NO20061455L - 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse - Google Patents
2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disseInfo
- Publication number
- NO20061455L NO20061455L NO20061455A NO20061455A NO20061455L NO 20061455 L NO20061455 L NO 20061455L NO 20061455 A NO20061455 A NO 20061455A NO 20061455 A NO20061455 A NO 20061455A NO 20061455 L NO20061455 L NO 20061455L
- Authority
- NO
- Norway
- Prior art keywords
- dioxopiperidine
- pharmaceutical preparations
- pharmaceutical compositions
- preparations containing
- isomers
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- CNMOHEDUVVUVPP-UHFFFAOYSA-N piperidine-2,3-dione Chemical compound O=C1CCCNC1=O CNMOHEDUVVUVPP-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4827897P | 1997-05-30 | 1997-05-30 | |
PCT/US1998/010886 WO1998054170A1 (en) | 1997-05-30 | 1998-05-28 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNFα LEVELS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20061455L true NO20061455L (no) | 2000-01-28 |
NO331367B1 NO331367B1 (no) | 2011-12-12 |
Family
ID=21953674
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19995751A NO322080B1 (no) | 1997-05-30 | 1999-11-23 | 2,6-dioksopiperidiner samt farmasoytiske preparater som inneholder disse. |
NO20061455A NO331367B1 (no) | 1997-05-30 | 2006-03-30 | 1-okso-2-(2,6 dioksopiperidin-3-yl)-4-aminoisoindolin samt farmasoytisk sammensetning inneholdende en slik forbindelse |
NO20092860A NO332270B1 (no) | 1997-05-30 | 2009-08-18 | Farmasoytisk sammensetning som omfatter 1,3-diokso-2-(2,6-dioksopiperidin-3-yl)-4-aminoisoindolin og en farmasoytisk akseptabel eksipiens, fortynningsmiddel eller baerer |
NO20111536A NO332271B1 (no) | 1997-05-30 | 2011-11-08 | 2,6-dioksopiperidiner, anvendelse derav samt fremgangsmate for fremstilling av et medikament som inneholder en slik forbindelse |
NO2012004C NO2012004I2 (no) | 1997-05-30 | 2012-03-06 | l-okso-2-(2,6-dioksopiperidin-3-yl)-4-aminoisoindolin i racemisk form eller R-eller S-isomerer derav |
NO20120330A NO333641B1 (no) | 1997-05-30 | 2012-03-20 | 2,6-dioksopiperidinderivater samt farmasoytiske preparater som inneholder disse |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19995751A NO322080B1 (no) | 1997-05-30 | 1999-11-23 | 2,6-dioksopiperidiner samt farmasoytiske preparater som inneholder disse. |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092860A NO332270B1 (no) | 1997-05-30 | 2009-08-18 | Farmasoytisk sammensetning som omfatter 1,3-diokso-2-(2,6-dioksopiperidin-3-yl)-4-aminoisoindolin og en farmasoytisk akseptabel eksipiens, fortynningsmiddel eller baerer |
NO20111536A NO332271B1 (no) | 1997-05-30 | 2011-11-08 | 2,6-dioksopiperidiner, anvendelse derav samt fremgangsmate for fremstilling av et medikament som inneholder en slik forbindelse |
NO2012004C NO2012004I2 (no) | 1997-05-30 | 2012-03-06 | l-okso-2-(2,6-dioksopiperidin-3-yl)-4-aminoisoindolin i racemisk form eller R-eller S-isomerer derav |
NO20120330A NO333641B1 (no) | 1997-05-30 | 2012-03-20 | 2,6-dioksopiperidinderivater samt farmasoytiske preparater som inneholder disse |
Country Status (25)
Country | Link |
---|---|
US (3) | US6395754B1 (no) |
EP (3) | EP1956017B1 (no) |
JP (2) | JP4307567B2 (no) |
KR (1) | KR100526212B1 (no) |
CN (3) | CN1258293A (no) |
AT (2) | ATE401319T1 (no) |
AU (1) | AU741982B2 (no) |
CA (2) | CA2669481C (no) |
CY (1) | CY1108348T1 (no) |
CZ (1) | CZ299812B6 (no) |
DE (2) | DE69825994T2 (no) |
DK (2) | DK0984955T3 (no) |
ES (3) | ES2403102T3 (no) |
FI (1) | FI19992490A (no) |
HK (1) | HK1072248A1 (no) |
HU (2) | HU228769B1 (no) |
MC (1) | MC225A7 (no) |
NO (6) | NO322080B1 (no) |
NZ (1) | NZ501429A (no) |
PL (1) | PL193276B1 (no) |
PT (2) | PT984955E (no) |
RU (1) | RU2209207C2 (no) |
SK (1) | SK163099A3 (no) |
TR (4) | TR200000107T2 (no) |
WO (1) | WO1998054170A1 (no) |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
PT1308444E (pt) * | 1997-11-18 | 2006-08-31 | Celgene Corp | 2-( 2,6-dioxo-3-fluoropiperidina-3-il )- isoindolinas e a sua utilizacao para reduzir os niveis de tnf |
BR9908811A (pt) * | 1998-03-16 | 2000-12-05 | Celgene Corp | Composto, composição farmacêutica e seu uso no tratamento de mamìferos |
ATE306469T1 (de) | 1999-03-18 | 2005-10-15 | Celgene Corp | Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ES2290091T3 (es) * | 2000-11-30 | 2008-02-16 | The Children's Medical Center Corporation | Sintesis de enantiomeros de 4-amino-talidomida. |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US20050148034A1 (en) * | 2002-04-12 | 2005-07-07 | Hariri Robert J. | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
EP1556033A4 (en) * | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
EP2915533B1 (en) | 2002-05-17 | 2017-09-13 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
AU2003228509B2 (en) * | 2002-10-15 | 2008-06-26 | Celgene Corporation | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
NZ540028A (en) * | 2002-10-24 | 2009-07-31 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
BR0315931A (pt) * | 2002-10-31 | 2005-09-13 | Celgene Corp | Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
BR0316057A (pt) | 2002-11-06 | 2005-09-20 | Celgene Corp | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit |
US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
CN1738613A (zh) * | 2002-11-18 | 2006-02-22 | 细胞基因公司 | 包含(+)-3-(3,4-二甲氧基-苯基)-3-(1-氧代-1,3-二氢-异吲哚-2-基)-丙酰胺的组合物及其使用方法 |
MXPA05005161A (es) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida. |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
US7612096B2 (en) | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
CN1901911A (zh) * | 2003-11-06 | 2007-01-24 | 细胞基因公司 | 使用沙利度胺治疗和控制癌症和其它疾病的组合物和方法 |
NZ547689A (en) | 2003-11-19 | 2009-05-31 | Signal Pharm Llc | Indazole compounds and methods of use thereof as protein kinase inhibitors |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
JP2007530544A (ja) * | 2004-03-22 | 2007-11-01 | セルジーン・コーポレーション | 皮膚疾患又は障害を治療及び管理するための免疫調節化合物の使用方法及びそれを含む組成物 |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
CA2563207A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
EP1744749A4 (en) * | 2004-04-14 | 2009-04-22 | Celgene Corp | METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES |
JP2007533761A (ja) * | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物 |
MXPA06012648A (es) * | 2004-05-05 | 2007-02-14 | Celgene Corp | Metodo de utilizacion y composiciones que comprenden compuestos inmunomodulatorios para el tratamiento y manejo de enfermedades mieloproliferativas. |
ZA200702382B (en) * | 2004-09-03 | 2008-08-27 | Celgene Corp | Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines |
EP1811992A2 (en) * | 2004-10-28 | 2007-08-01 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
WO2006058008A1 (en) * | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
JP2008528514A (ja) * | 2005-01-25 | 2008-07-31 | セルジーン・コーポレーション | 4−アミノ−2−(3−メチル−2,6−ジオキソピペリジン−3−イル)−イソインドール−1,3−ジオンを使用する方法及び組成物 |
CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物 |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
US20070038298A1 (en) * | 2005-06-30 | 2007-02-15 | Sulner Joseph W | Repair of tympanic membrane using placenta derived collagen biofabric |
AU2006265019B2 (en) * | 2005-06-30 | 2011-10-13 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
EP1919365A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Ocular plug formed from placenta derived collagen biofabric |
WO2007009062A2 (en) | 2005-07-13 | 2007-01-18 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
CA2899923A1 (en) | 2005-08-31 | 2007-03-08 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
RS51840B (en) | 2005-09-01 | 2012-02-29 | Celgene Corporation | IMMUNOLOGICAL APPLICATIONS OF IMMUNOMODULATORY UNITS FOR VACCINE AND FOR INFECTIOUS DISEASE THERAPY |
US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物 |
NZ597304A (en) | 2005-10-13 | 2013-06-28 | Anthrogenesis Corp | Immunomodulation using placental stem cells |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
KR20080097190A (ko) * | 2005-12-29 | 2008-11-04 | 안트로제네시스 코포레이션 | 태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법 |
US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
US8105634B2 (en) | 2006-08-15 | 2012-01-31 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
RU2448101C2 (ru) * | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
AU2007290407A1 (en) * | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
US20080131522A1 (en) * | 2006-10-03 | 2008-06-05 | Qing Liu | Use of placental biomaterial for ocular surgery |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
NZ576372A (en) | 2006-10-06 | 2012-02-24 | Anthrogenesis Corp | Native (telopeptide) placental collagen compositions |
CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
CN103356711A (zh) | 2007-02-12 | 2013-10-23 | 人类起源公司 | 利用胎盘干细胞治疗炎性疾病 |
JP2010518812A (ja) * | 2007-02-12 | 2010-06-03 | アンスロジェネシス コーポレーション | 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにcd34+、cd45−胎盤幹細胞の濃縮細胞集団 |
WO2009020590A1 (en) * | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
CN104211684A (zh) | 2007-09-26 | 2014-12-17 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
AU2008307633C1 (en) | 2007-09-28 | 2015-04-30 | Celularity Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
EP2235213A2 (en) | 2007-12-20 | 2010-10-06 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
WO2009105256A2 (en) * | 2008-02-20 | 2009-08-27 | Celgene Corporation | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
MX2011004470A (es) | 2008-10-29 | 2011-05-31 | Celgene Corp | Compuestos de isoindolina para uso en el tratamiento de cancer. |
US20120053159A1 (en) | 2009-02-11 | 2012-03-01 | Muller George W | Isotopologues of lenalidomide |
AU2010229711B2 (en) | 2009-03-25 | 2015-06-04 | Celularity Inc. | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
TR201905423T4 (tr) | 2009-05-19 | 2019-05-21 | Celgene Corp | 4-amino-2-(2,6-dioksopiperidin-3-il)izindolin-1,3-dion'un formülasyonları |
JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
WO2011079091A1 (en) | 2009-12-22 | 2011-06-30 | Celgene Corporation | (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
EP2851070A1 (en) | 2010-01-05 | 2015-03-25 | Celgene Corporation | A combination of lenalidomide and artesunate/artemisone for treating cancer |
MX337169B (es) | 2010-02-11 | 2016-02-16 | Celgene Corp | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos. |
MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
WO2012078492A1 (en) | 2010-12-06 | 2012-06-14 | Celgene Corporation | A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
EP2663549B1 (en) | 2011-01-10 | 2018-03-14 | Celgene Corporation | Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines |
SG192946A1 (en) | 2011-03-11 | 2013-09-30 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
WO2012145309A1 (en) | 2011-04-18 | 2012-10-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
ES2707579T3 (es) | 2011-06-01 | 2019-04-04 | Celularity Inc | Tratamiento del dolor usando citoblastos placentarios |
US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
MX356105B (es) | 2011-09-14 | 2018-05-14 | Celgene Corp | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. |
PL2797581T3 (pl) | 2011-12-27 | 2020-10-05 | Amgen (Europe) GmbH | Formulacje (+)-2-[1-(3-etoksy-4-metoksy-fenylo)-2-metanosulfonylo-etylo]- 4acetyloaminoizoindolino-1,3-dionu |
US20150174235A1 (en) | 2012-06-06 | 2015-06-25 | Bionor Immuno As | Vaccine |
ES2699810T3 (es) | 2012-06-29 | 2019-02-12 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon |
WO2014018866A1 (en) | 2012-07-27 | 2014-01-30 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
CN104703978B (zh) | 2012-08-09 | 2018-05-11 | 细胞基因公司 | 化合物的盐和固体形式及其组合物和使用方法 |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
BR112015005243A2 (pt) | 2012-09-10 | 2017-07-04 | Celgene Corp | métodos para o tratamento de câncer de mama localmente avançado |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
JP6389241B2 (ja) | 2013-04-17 | 2018-09-12 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのTORキナーゼ阻害剤及びIMiD化合物を含む組合せ療法 |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
PL3182996T3 (pl) | 2014-08-22 | 2023-04-17 | Celgene Corporation | Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami |
DK3214081T3 (da) | 2014-10-30 | 2020-09-28 | Kangpu Biopharmaceuticals Inc | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf |
SI3313818T1 (sl) | 2015-06-26 | 2024-03-29 | Celgene Corporation | Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
ITUB20169994A1 (it) | 2016-01-14 | 2017-07-14 | Phf Sa | Nuove forme cristalline di farmaci immunomodulatori |
CA3045508A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
CA3061945A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
JP2020526194A (ja) | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
US20200246393A1 (en) | 2017-09-28 | 2020-08-06 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
EP3724225A1 (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
US11401336B2 (en) | 2018-02-21 | 2022-08-02 | Celgene Corporation | BCMA-binding antibodies and uses thereof |
JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー4 セラピューティクス, インコーポレイテッド | Ikarosの分解のためのセレブロン結合剤 |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
AU2019377854A1 (en) | 2018-11-08 | 2021-05-27 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
EP3880669A1 (en) | 2018-11-13 | 2021-09-22 | Biotheryx, Inc. | Substituted isoindolinones |
JP2022513062A (ja) | 2018-11-16 | 2022-02-07 | ジュノー セラピューティクス インコーポレイテッド | B細胞悪性腫瘍を処置するために、操作されたt細胞を投薬する方法 |
JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
PE20212198A1 (es) | 2019-01-29 | 2021-11-16 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) |
EP3935050A4 (en) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT |
JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス, インコーポレイテッド | イソインドリノン化合物 |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3378763D1 (en) * | 1982-04-02 | 1989-02-02 | Takeda Chemical Industries Ltd | Condensed pyrrolinone derivatives, and their production |
US4849441A (en) * | 1986-12-25 | 1989-07-18 | Kyowa Hakko Kogyo Co., Ltd. | Isoindolin-1-one derivative and antiarrhythmic agent |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
DK24089D0 (da) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
DE4211812C2 (de) * | 1991-04-17 | 1994-05-05 | Gruenenthal Gmbh | Thalidomidderivate, ein Verfahren zu deren Herstellung sowie die Verwendung derselben in Arzneimitteln |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US20010056114A1 (en) | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
DE4422237A1 (de) * | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe |
US5795368A (en) * | 1996-03-01 | 1998-08-18 | O.I. Corporation | Microtrap sample concentrator and methods of use |
DE19613976C1 (de) * | 1996-04-09 | 1997-11-20 | Gruenenthal Gmbh | Thalidomid-Prodrugs mit immunmodulatorischer Wirkung |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
ES2529190T3 (es) * | 1996-07-24 | 2015-02-17 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
NZ334148A (en) | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
DE69740095D1 (de) | 1996-11-05 | 2011-02-17 | Childrens Medical Center | Thalidomide und Dexamethason für die Behandlung von Tumors |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
BR9908811A (pt) * | 1998-03-16 | 2000-12-05 | Celgene Corp | Composto, composição farmacêutica e seu uso no tratamento de mamìferos |
US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
EE04799B1 (et) * | 1999-03-12 | 2007-04-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid |
ATE306469T1 (de) | 1999-03-18 | 2005-10-15 | Celgene Corp | Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
CN1420776A (zh) | 2000-03-31 | 2003-05-28 | 塞尔基因公司 | 环氧合酶-2活性的抑制 |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ES2290091T3 (es) | 2000-11-30 | 2008-02-16 | The Children's Medical Center Corporation | Sintesis de enantiomeros de 4-amino-talidomida. |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
EP1389203B8 (en) | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
NZ531294A (en) | 2001-08-06 | 2005-11-25 | Childrens Medical Center | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US20050148034A1 (en) | 2002-04-12 | 2005-07-07 | Hariri Robert J. | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
EP2915533B1 (en) | 2002-05-17 | 2017-09-13 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
NZ540028A (en) | 2002-10-24 | 2009-07-31 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
BR0315931A (pt) | 2002-10-31 | 2005-09-13 | Celgene Corp | Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
EP1694328A4 (en) | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
JP2007530544A (ja) | 2004-03-22 | 2007-11-01 | セルジーン・コーポレーション | 皮膚疾患又は障害を治療及び管理するための免疫調節化合物の使用方法及びそれを含む組成物 |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
EP1744749A4 (en) | 2004-04-14 | 2009-04-22 | Celgene Corp | METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES |
JP2007533761A (ja) | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物 |
MXPA06012648A (es) | 2004-05-05 | 2007-02-14 | Celgene Corp | Metodo de utilizacion y composiciones que comprenden compuestos inmunomodulatorios para el tratamiento y manejo de enfermedades mieloproliferativas. |
-
1997
- 1997-07-24 HU HU9903929A patent/HU228769B1/hu active Protection Beyond IP Right Term
-
1998
- 1998-05-28 WO PCT/US1998/010886 patent/WO1998054170A1/en active Application Filing
- 1998-05-28 AT AT04077432T patent/ATE401319T1/de active
- 1998-05-28 ES ES08009864T patent/ES2403102T3/es not_active Expired - Lifetime
- 1998-05-28 NZ NZ501429A patent/NZ501429A/en not_active IP Right Cessation
- 1998-05-28 EP EP20080009864 patent/EP1956017B1/en not_active Expired - Lifetime
- 1998-05-28 ES ES04077432T patent/ES2309443T3/es not_active Expired - Lifetime
- 1998-05-28 DE DE1998625994 patent/DE69825994T2/de not_active Expired - Lifetime
- 1998-05-28 ES ES98924959T patent/ES2229497T3/es not_active Expired - Lifetime
- 1998-05-28 CA CA 2669481 patent/CA2669481C/en not_active Expired - Fee Related
- 1998-05-28 TR TR200000107T patent/TR200000107T2/xx unknown
- 1998-05-28 US US09/445,002 patent/US6395754B1/en not_active Expired - Lifetime
- 1998-05-28 RU RU99128073A patent/RU2209207C2/ru not_active IP Right Cessation
- 1998-05-28 EP EP20040077432 patent/EP1486496B1/en not_active Expired - Lifetime
- 1998-05-28 HU HU0003217A patent/HU229578B1/hu not_active IP Right Cessation
- 1998-05-28 TR TR201005282T patent/TR201005282T2/xx unknown
- 1998-05-28 TR TR200500299T patent/TR200500299T2/xx unknown
- 1998-05-28 EP EP19980924959 patent/EP0984955B1/en not_active Expired - Lifetime
- 1998-05-28 CN CN98805614A patent/CN1258293A/zh active Pending
- 1998-05-28 PT PT98924959T patent/PT984955E/pt unknown
- 1998-05-28 DK DK98924959T patent/DK0984955T3/da active
- 1998-05-28 KR KR10-1999-7011076A patent/KR100526212B1/ko not_active IP Right Cessation
- 1998-05-28 AU AU77012/98A patent/AU741982B2/en not_active Ceased
- 1998-05-28 AT AT98924959T patent/ATE275139T1/de active
- 1998-05-28 DE DE69839739T patent/DE69839739D1/de not_active Expired - Lifetime
- 1998-05-28 CN CNA2006101262647A patent/CN1911927A/zh active Pending
- 1998-05-28 CN CNA2005100525903A patent/CN1680367A/zh active Pending
- 1998-05-28 CZ CZ0427899A patent/CZ299812B6/cs not_active IP Right Cessation
- 1998-05-28 PL PL337124A patent/PL193276B1/pl unknown
- 1998-05-28 PT PT04077432T patent/PT1486496E/pt unknown
- 1998-05-28 DK DK04077432T patent/DK1486496T3/da active
- 1998-05-28 JP JP50090999A patent/JP4307567B2/ja not_active Expired - Fee Related
- 1998-05-28 SK SK1630-99A patent/SK163099A3/sk unknown
- 1998-05-28 CA CA 2291218 patent/CA2291218C/en not_active Expired - Fee Related
- 1998-05-28 TR TR200801878T patent/TR200801878T2/xx unknown
-
1999
- 1999-11-23 NO NO19995751A patent/NO322080B1/no not_active IP Right Cessation
- 1999-11-23 FI FI992490A patent/FI19992490A/fi unknown
-
2002
- 2002-05-10 US US10/143,416 patent/US20020173658A1/en not_active Abandoned
-
2005
- 2005-01-14 US US11/035,817 patent/US7459466B2/en not_active Expired - Fee Related
- 2005-03-08 HK HK05102027A patent/HK1072248A1/xx not_active IP Right Cessation
- 2005-08-11 MC MC225K patent/MC225A7/xx unknown
-
2006
- 2006-03-30 NO NO20061455A patent/NO331367B1/no not_active IP Right Cessation
-
2008
- 2008-09-17 CY CY081101005T patent/CY1108348T1/el unknown
-
2009
- 2009-02-06 JP JP2009025981A patent/JP2009138009A/ja active Pending
- 2009-08-18 NO NO20092860A patent/NO332270B1/no not_active IP Right Cessation
-
2011
- 2011-11-08 NO NO20111536A patent/NO332271B1/no not_active IP Right Cessation
-
2012
- 2012-03-06 NO NO2012004C patent/NO2012004I2/no unknown
- 2012-03-20 NO NO20120330A patent/NO333641B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061455L (no) | 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse | |
NO954342L (no) | Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav | |
MY141773A (en) | (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors | |
IL123002A0 (en) | 1-Phenyl-2- phenylacetoxy- ethanone derivatives | |
MY128654A (en) | Liquid pharmaceutical composition containing an erythropoietin derivative | |
BG101841A (en) | Cellular adhesion inhibitors | |
DE69326776D1 (de) | Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress | |
NO180538C (no) | N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer, farmasöytiske blandinger som inneholder dem og mellomprodukter ved fremstilling av derivatene | |
NO305596B1 (no) | 1-(2-okso-acetyl)-piperidin-2-karboksylsyrederivater som multi-medikamentresistente sensitivisatorer for kreftceller | |
DE69729786D1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
GEP20063885B (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | |
NO972451L (no) | Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav | |
EP0705100A4 (en) | THERAPEUTIC SUBSTITUTED GUANIDINES | |
AU2740797A (en) | Androstene derivatives | |
TR199802534T2 (xx) | Leptin (OB Protein) fragmanlar� | |
MX9403088A (es) | Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso. | |
NZ240481A (en) | Aminosulphonyl urea derivatives and pharmaceutical compositions | |
CA2218663A1 (en) | Benzisoxazole and indazole derivatives as antipsychotic agents | |
DE69715173D1 (en) | Bisarylcyclobutenderivate als cyclooxygenasehemmer | |
NO20000519L (no) | 2-acylaminopropanaminer som takykininreseptorantagonister | |
DE69816047D1 (en) | (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer | |
BG103632A (en) | Pharmaceutical compositions containing ibuprophene and domperidon for migraine treatment | |
DK0758312T3 (da) | Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler | |
EA199700243A1 (ru) | Производное аминотетралина для лечения сердечно-сосудистых заболеваний | |
GEP20032975B (en) | Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO |
|
BDEC | Board of appeal decision |
Free format text: FORSTE AVDELINGS AVGJOELSE AV 25. MARS 2009, HVORVED SOKNAD OM PATENT BLE AVSLATT, ER DEN 8. MARS 2011 BESLUTTET OPPHEVET AV PATENTSTYRETS ANNEN AVDELING. I KJENNELSEN AV 8. MARS 2011 UTTALER PATENTSTYRETS ANNEN AVDELING: "FORSTE AVDELINGS AVGJORELSE OPPHEVES, OG SAKEN SENDES TILBAKE TIL FUERSTE AVDELING FOR MEDDELELSE AV PATENT." ANNEN AVDELING AVGJORELSE KAN IKKE PAANKES, OG ER ALLEREDE RETTSKRAFTIG. |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: REVLIMID - LENALIDOMIDE; NAT. REG. NO/DATE: EU/1/07/391/001-004 20070713; FIRST REG. NO/DATE: 07/391/001-004 20070614 Spc suppl protection certif: 2012004 Filing date: 20120306 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: REVLIMID - LENALIDOMIDE; NAT. REG. NO/DATE: EU/1/07/391/001-004 20070713; FIRST REG. NO/DATE: 07/391/001-004 20070614 Spc suppl protection certif: 2012004 Filing date: 20120306 Extension date: 20220614 |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Spc suppl protection certif: 2012004 |